- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05110742
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary objective:
To determine the safety, efficacy and optimal cell dose of CAR.5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia. The efficacy and optimal dose will be identified for individual diseases.
Secondary Objectives:
- To assess the overall response rate (complete and partial response rates)
- To quantify persistence of infused allogeneic donor CAR-transduced CB-derived NK cells in -To conduct comprehensive immune reconstitution studies.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Chitra Hosing
- Phone Number: (713) 745-3219
- Email: cmhosing@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Contact:
- Chitra Hosing
- Phone Number: 713-745-3219
- Email: cmhosing@mdanderson.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- Patients with hematological malignances with an expression of CD5 in the pre-enrollment tumor sample ≥ 30% measured by immunohistochemistry or flow cytometry.
- Patients must meet diseases specific eligibility criteria (see below)
- Patients should be at least 3 weeks from last cytotoxic chemotherapy at the time of starting lymphodepleting chemotherapy. Patients may continue tyrosine kinase inhibitors or other targeted therapies until at least three days prior to administration of lymphodepleting chemotherapy.
- Localized radiotherapy to one or more disease sites are allowed prior the infusion provided that there are additional disease sites that are not irradiated
- Karnofsky Performance Scale > 50%.
Adequate organ function:
- Renal: Serum creatinine ≤ 1.5 mg/dL or estimated Glomerular Filtration Rate (eGFR using the CKI-EPI equation) ≥ 60 ml/min/1.73 m2.
- Hepatic: ALT/AST ≤ 2.5 x ULN or ≤ 5 x ULN if documented liver involvement with disease, Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert's Syndrome in whom total bilirubin must be ≤ 3.0 mg/dL. No history of liver cirrhosis. No ascites.
- Cardiac: Cardiac ejection fraction ≥ 50%, no clinically significant pericardial effusion as determined by an ECHO or MUGA, and no uncontrolled arrhythmias or symptomatic cardiac disease.
- Pulmonary: No clinically significant lung involvement, per PI discretion, pleural effusion, baseline oxygen saturation > 92% on room air.
- Able to provide written informed consent.
- 18-80 years of age.
- Weight ≥40 kg
- All participants who are able to have children must practice effective birth control while on study and up to 3 months post completion of study therapy. Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study. If the participant is a female and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If the participant becomes pregnant during this study, she will be taken off this study. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctor.
- Signed consent to long-term follow-up protocol PA17-0483.
- Disease specific inclusion criteria A. T-cell non-Hodgkin's lymphoma and T-cell acute lymphoblastic leukemia
1. Patients with history of T-lymphoid malignancies, defined as acute lymphoblastic leukemia (ALL/T-LBL), Peripheral T-cell lymphoma (PTCL-NOS, MF/SS, Hepatosplenic gamma/delta NHL, AITL, ALCL) who have received at least 2 lines of standard chemo-immunotherapy or targeted therapy and have measurable persistent disease. For T-ALL active disease defined as (>5% of blasts or positive MRD at a level of >0.1% measured by multiparameter flow cytometry).
2. Patients with history of T-lymphoid malignancies as defined above with relapsed disease following standard therapy or a stem cell transplant.
B. Chronic lymphocytic leukemia (CLL) Chronic lymphocytic leukemia (CLL) small lymphocytic lymphoma (SLL), Richter's transformation of CLL or SLL who have received at least 2 lines of standard chemoimmunotherapy or targeted therapy and have persistent disease C. Mantle cell lymphoma Relapsed or refractory mantle cell lymphoma after 2 lines of standard chemoimmunotherapy including a BTKi
Exclusion criteria:
- Positive beta HCG in female of child-bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females.
- Presence of clinically significant Grade 3 or greater toxicity from the previous treatment, as determined by PI.
- Presence of uncontrolled fungal, bacterial, viral, or other infection not responding to appropriate therapy.
- Active hepatitis B or C.
- HIV with detectable viral load
- Presence of active neurological disorder(s).
- Active autoimmune disease within 12 months of enrollment
- Active cerebral or meningeal involvement by the malignancy
- Active (defined as requiring therapy) acute or chronic GVHD
- Any other malignancy known to be active, except for treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.
- Presence of any other serious medical condition that may endanger the patient at investigator criteria
- Major surgery <4 weeks prior to first dose of study drug
- Allogeneic SCT or DLI <12 weeks prior to first dose of study drug
- Concomitant use of other investigational agents.
- Concomitant use of other anti-cancer agents.
- Patients receiving systemic steroid therapy at time of enrollment (physiological substitutive doses are allowed), or have received ATG within 14 days or Campath within 28 days of enrollment.
- Patients receiving immunosuppressive therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1 Dose Level
CAR.5/IL15-transduced CB-NK cells Dose level 1, 1e7 cryopreserved cells flat dose Dose level 2, 1e8 cryopreserved cells flat dose Dose level 3, 1e9 cryopreserved cells flat dose Dose level 4, 1e10 cryopreserved cells flat dose All patients will receive Lymphodepleting Chemotherapy of Cyclophosphamide and Fludarabine. |
Given by IV
Other Names:
Given by IV
Other Names:
Given by IV
|
Experimental: Phase 2 Dose Level
Patients will be randomized between the 2 optimal doses of CAR.5/IL15-transduced CB-NK cells determined by Phase 1. All patients will receive Lymphodepleting Chemotherapy of Cyclophosphamide and Fludarabine. |
Given by IV
Other Names:
Given by IV
Other Names:
Given by IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0.
Time Frame: through study completion, an average of 1 year
|
General grading: Grade 1: Mild: discomfort present with no disruption of daily activity, no treatment required beyond prophylaxis. Grade 2: Moderate: discomfort present with some disruption of daily activity, require treatment. Grade 3: Severe: discomfort that interrupts normal daily activity, not responding to first line treatment. Grade 4: Life Threatening: discomfort that represents immediate risk of death |
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: chitra hosing, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Hematologic Diseases
- Hematologic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
- Fludarabine phosphate
Other Study ID Numbers
- 2021-0526
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancy
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Henry Ford Health SystemRecruitingHematological MalignancyUnited States
-
SanofiCompletedHematological MalignancyGreece, Spain, Peru, Israel, United States, Argentina, Belgium, Brazil, Chile, Finland, France, Italy, Mexico, Russian Federation, Turkey, Ukraine, United Kingdom
-
University of CopenhagenZealand University HospitalEnrolling by invitationHematological MalignancyDenmark
-
Washington University School of MedicineBarnes-Jewish HospitalTerminatedHematological MalignancyUnited States
-
Institut Paoli-CalmettesCompletedHematological MalignancyFrance
-
Peking University People's HospitalSanofiRecruitingHematological MalignancyChina
-
Beckman Coulter, Inc.Completed
-
Fate TherapeuticsTerminatedHematological MalignancyUnited States
-
University Hospital, Strasbourg, FranceUnknownHematological MalignancyFrance
Clinical Trials on Fludarabine Phosphate
-
NCIC Clinical Trials GroupCompleted
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative DiseasesUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)UnknownGraft Versus Host Disease
-
Genzyme, a Sanofi CompanyCompleted
-
M.D. Anderson Cancer CenterVion PharmaceuticalsCompletedHematologic MalignanciesUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHead and Neck CancerUnited States
-
St. Petersburg State Pavlov Medical UniversityRecruitingMultiple SclerosisRussian Federation